(Q38038317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

E J Cameron

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C McSharry

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

R Chaudhuri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Farrow

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

Clinical & Experimental Allergy

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1302-1312

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22925316%20AND%20SRC:MED&resulttype=core&format=json

Macrolides and ketolides: azithromycin, clarithromycin, telithromycin

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

A trial of clarithromycin for the treatment of suboptimally controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

The effect of telithromycin in acute exacerbations of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin for prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

British Thoracic Society guideline for non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Alternative activation of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin alters macrophage phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Effect of clarithromycin on rhinovirus-16 infection in A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin induces anti-viral responses in bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Oral erythromycin and the risk of sudden death from cardiac causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Meta-analysis of bacterial resistance to macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X

Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2012.03979.X